
USD
$0.00
(0.00%
)At Close (As of Nov 13, 2025)
$7.43B
Market Cap
-
P/E Ratio
-2.99
EPS
$83.86
52 Week High
$12.30
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | -$14K |
| Total Revenue | $0 |
| Cost Of Revenue | $14K |
| Costof Goods And Services Sold | $14K |
| Operating Income | -$225M |
| Selling General And Administrative | $27M |
| Research And Development | $108M |
| Operating Expenses | $225M |
| Investment Income Net | - |
| Net Interest Income | $6M |
| Interest Income | $6.2M |
| Interest Expense | $223K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14K |
| Income Before Tax | -$218M |
| Income Tax Expense | -$9.3M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$209M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$218M |
| Ebitda | -$218M |
| Net Income | -$209M |
| Field | Value (USD) |
|---|---|
| Gross Profit | -$14K |
| Total Revenue | $0 |
| Cost Of Revenue | $14K |
| Costof Goods And Services Sold | $14K |
| Operating Income | -$225M |
| Selling General And Administrative | $27M |
| Research And Development | $108M |
| Operating Expenses | $225M |
| Investment Income Net | - |
| Net Interest Income | $6M |
| Interest Income | $6.2M |
| Interest Expense | $223K |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $14K |
| Income Before Tax | -$218M |
| Income Tax Expense | -$9.3M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$209M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$218M |
| Ebitda | -$218M |
| Net Income | -$209M |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Metsera, Inc. is a clinical-stage biotechnology firm based in New York, focused on developing cutting-edge injectable and oral hormone analog peptides designed for obesity and related metabolic disorders. Leveraging advanced peptide technology, the company aspires to transform obesity treatment through its innovative therapeutic solutions. With a strong pipeline and a commitment to scientific advancement, Metsera presents significant growth potential within the health and wellness sector, making it an appealing investment opportunity for institutional investors interested in the evolving biotech industry.